Company intelligence / Profile preview
Catapult Therapeutics
's-Hertogenbosch / Den Bosch, Noord-Brabant, Netherlandscatapult-therapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 1
01
Overview
Catapult Therapeutics is conducting a Phase 1 clinical trial of CAP-100, a first-in-class humanized anti-CCR7 monoclonal antibody, in patients with relapsed or refractory CLL. The study aims to evaluate safety, tolerability, pharmacokinetics/dynamics, and preliminary efficacy. Preclinical data showed CAP‑100 can inhibit cancer cell migration to lymph nodes and induce tumor cell killing while sparing normal blood cells. The trial is being conducted at Dana-Farber Cancer Institute and other US sites[5][6].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Humanized IgG1 antibody[3][5][6]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Dana-Farber Cancer Institute (clinical collaboration)[5]Academic collaborations with Hospital La Princesa in Madrid for foundational research[1]Technology partnership with Pepscan for antibody generation platform[1]
Beyond the preview
Go deeper on Catapult Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catapult Therapeutics.